Overview

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Status:
Active, not recruiting

Trial end date:
2022-08-19

Target enrollment:

Participant gender:

Summary

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Crizotinib